Methods and compositions for treating conditions
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/07
A61K-038/12
출원번호
UP-0692847
(2007-03-28)
등록번호
US-7557088
(2009-07-15)
발명자
/ 주소
Skubatch, Hanna
출원인 / 주소
NeoPro Labs, LLC
대리인 / 주소
Wilson, Sonsini, Goodrich & Rosati
인용정보
피인용 횟수 :
7인용 특허 :
11
초록▼
The invention relates to compositions that can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for administration to a human or a pla
The invention relates to compositions that can be used to treat, prevent, and modulate pain, inflammation, and metabolic processes in various organisms including plants and animals. Such compositions can be formulated with an acceptable pharmaceutical excipient for administration to a human or a plant. The compositions can be administered topically or for systemic use.
대표청구항▼
What is claimed is: 1. A composition comprising: a polypeptide comprising SEQ ID NO:1; and a compound selected from the group consisting of: Alvimopan; trans-3,4-dimethyl-4-(3-hydroxyphenly)piperidine; ANTI: 5'-acetamidinoethylnaltrindole; 4-Aminoquinoline; N-(4-amino-2-methylquinolin-6-yl)-2-(4-et
What is claimed is: 1. A composition comprising: a polypeptide comprising SEQ ID NO:1; and a compound selected from the group consisting of: Alvimopan; trans-3,4-dimethyl-4-(3-hydroxyphenly)piperidine; ANTI: 5'-acetamidinoethylnaltrindole; 4-Aminoquinoline; N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide monohydrochloride; Benzimidazolinone; 7-Benzylidenenaltrexone; Binaltorphimine; nor-Binaltorphimine; Butorphanol: 17-cyclobutylmethyl-3,14-dihydroxymorphinan tartrate; CTAP: D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2; CTOP: D-Phe-Cys-Try-D-Trp-Orn-Thr-Pen-Thr-NH2; Cyclazocine; Cyprodime; 1,3-Dimethyl-4-piperidinone; Ethylketocyclazocine; β-Funaltrexamine; GNTI: 5'-Guanidinonaltrindole; ICI 174864: N,N-diallyl-Tyr-Aib-Aib-Phe-Leu; Indolomorphinan; 5'-Isothiocyanate; J-113397: 1-[(3R,4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one; JDTic: (3R)-7-Hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3, 4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-1,2,3, 4-tetrahydro-3-isoquinoline-carboxamide; Quadazocine; Loperamide; Methoxynaltrexone; Methylnaltrexone; Mr 2266; Nalmefene: Nalorphine; Naloxone; Naloxone methiodide; Naloxazone; Naltrexone; β-Naltrexamine; Naltriben; Naltrindole; Phenylpiperidine; SB 612111: (5S,7S)-7-{[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl}-1-methyl-6,7,8, 9-tetrahydro-5H-benzo[7]annulen-5-ol; SoRI 9409: 5'-(4-chlorophenyl)-17-(cyclopropylmethyl)-6,7-didehydro-3,14-dihydroxy-4, 5alpha-epoxypyrido-[2',3':6,7]morphinan; SNC 80; TIPP[y]; and Triethyleneglycolnaltrexamine. 2. The composition of claim 1, wherein said polypeptide comprises SEQ ID NO: 2-3, 5, 8-11, 50 or 54. 3. A method for treating an addiction, comprising administering the composition of claim 1 to a patient in need thereof. 4. The method of claim 3 wherein said addiction is selected from the group consisting of alcoholism, addiction to cocaine, addiction to morphine, and addiction to heroine. 5. The method of claim 3, wherein said addiction is addiction to a painkiller. 6. An isolated cyclic peptide comprising SEQ ID NO: 1. 7. A composition comprising: an isolated cyclic peptide comprising SEQ ID NO: 1; and a compound selected from the group consisting of: Alvimopan; trans-3,4-dimethyl-4-(3-hydroxyphenly)piperidine; ANTI: 5'-acetamidinoethylnaltrindole; 4-Aminoquinoline; N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide monohydrochloride; Benzimidazolinone; 7-Benzylidenenaltrexone; Binaltorphimine; nor-Binaltorphimine; Butorphanol: 17-cyclobutylmethyl-3,14-dihydroxymorphinan tartrate; CTAP: D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2; CTOP: D-Phe-Cys-Try-D-Trp-Orn-Thr-Pen-Thr-NH2; Cyclazocine; Cyprodime; 1,3-Dimethyl-4-piperidinone; Ethylketocyclazocine; β-Funaltrexamine; GNTI: 5'-Guanidinonaltrindole; ICI 174864: N,N-diallyl-Tyr-Aib-Aib-Phe-Leu; Indolomorphinan; 5'-Isothiocyanate; J-113397: 1-[(3R,4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one; JDTic: (3R)-7-Hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3, 4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-1,2,3, 4-tetrahydro-3-isoquinoline-carboxamide; Quadazocine; Loperamide; Methoxynaltrexone; Methylnaltrexone; Mr 2266; Nalmefene: Nalorphine; Naloxone; Naloxone methiodide; Naloxazone; Naltrexone; β-Naltrexamine; Naltriben; Naltrindole; Phenylpiperidine; SB 612111: (5S,7S)-7-{[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl}-1-methyl-6,7,8, 9-tetrahydro-5H-benzo[7]annulen-5-ol; SoRI 9409: 5'-(4-chlorophenyl)-17-(cyclopropylmethyl)-6,7-didehydro-3,14-dihydroxy-4, 5alpha-epoxypyrido-[2',3':6,7]morphinan; SNC 80; TIPP[y]; and Triethyleneglycolnaltrexamine.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (11)
Maria A. Vitiello ; Robert W. Chestnut ; Alessandro D. Sette ; Esteban Celis ; Howard Grey, Compositions and methods for eliciting CTL immunity.
Vertesy Lszl (Eppstein/Taunus DEX) Geisen Karl (Frankfurt am Main DEX) Riess Gnther J. (Frankfurt am Main DEX) Sauber Klaus (Bad Soden am Taunus DEX), Insulin derivatives, a process for the preparation thereof, the use thereof, and a pharmaceutical formulation containing.
Bridon, Dominique P.; Ezrin, Alan M.; Milner, Peter G.; Holmes, Darren L.; Thibaudeau, Karen, Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.